Efficacy of methotrexate in comparison to biologies in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Rau, R ^a  

^a NONE   (Germany)

Author keywords

Biologics; Methotrexate; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; ETANERCEPT; FOLIC ACID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANAKINRA; C REACTIVE PROTEIN;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE RADIOGRAPHY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; IMMUNOGENICITY; OSTEOCLAST; PROBABILITY; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 78650584428     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BATHON JM, MARTINI RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 2000;343:1586-93.
2. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1443-50.
3. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
4. KLARESKOG L, VAN DER HEUDE D, DE JAGER J et al.: Therapuetic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
5. VAN DER HEUDE D, KLARESKOG L, RODRIGUEZ-VALVERDE V et al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum 2006;54:1063-74.
6. VAN DER HEUDE D, KLARESKOG L, LANDEWÉ G et al.: Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39.
7. EMERY P, BREEDVELD FC, HALL S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. Published online July 16, 2008.
8. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
9. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
10. MAINI R, ST CLAIR EW, BREEDVELT F et al.: Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexates randomized phase III trial. Lancet 1999;354:1932-39.
11. KEYSTONE E, VAN DER HEIJDE D, MASON D et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008;58:3319-29.
12. COHEN SB, MORELAND LW, CUSH JJ et al.: A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8
13. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
14. EDWARDS J C W, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
15. COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
16. KREMER JM, GENANT HK, MORELAND LW et al.: Effects of abatacept with methotrexate-resistent active rheumatoid arthritis, a randomized trial. Ann Intern Med 2006;144, 12:865-76.
17. VAN EDE AE, LAAN RF, ROOD MJ et al.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicernter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
18. STENGER A A M E, HOUTMAN PM, BRUYN G A W: Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate (review). Ann Rheum Dis 1992;51:1019-20.